Recent Posts
- CereMark Pharma Begins Phase III Trial of F-18 Flornaptitril, a Novel Diagnostic Radiopharmaceutical Focused on Neurodegeneration
- CereMark Pharma and Hall of Fame Health Team Up to Investigate the Clinical Progression of Neurodegeneration in Athletes and Soldiers
- CereMark Pharma and Invicro to Collaborate on the Development of F-18 Flornaptitril
- CereMark Pharma Announces New Patents on Selective Imaging Agent of Alzheimer’s Disease, Chronic Traumatic Encephalopathy and Other Neurodegenerative Diseases
- Patent Awarded for PET Radiopharmaceutical for Neurodegeneration Imaging